TLSA Tiziana Life Sciences PLC ADS

Tiziana Life Sciences PLC Directorate Change

Tiziana Life Sciences PLC Directorate Change

LONDON and NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor MacRae is standing down as a director of the Company with immediate effect.

Gabriele Cerrone, Chairman of Tiziana, said "I thank Gregor for his contribution to the Board and the Company and wish him well in his other interests. We are currently in the process of recruiting a new, seasoned non-executive director with extensive NASDAQ audit committee experience and hope to make a formal announcement shortly".

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

For further enquiries: 

United Kingdom: 
Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 
+44 (0)20 7493 2379
  
Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

+44 (0)20 7213 0880
  
Optiva Securities Limited (Broker)

Robert Emmet
+ 44 (0)20 3981 4173
  

United States:

Investors -

CORE IR

(516) 222-2560



Media

Jules Abraham

CORE IR

(917) 885-7378



For more information go to

EN
18/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tiziana Life Sciences PLC ADS

 PRESS RELEASE

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atr...

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an un...

 PRESS RELEASE

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foraluma...

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab. Transcriptional analysis of white blood cells before and ...

 PRESS RELEASE

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal For...

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoin...

 PRESS RELEASE

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences to Present at the Bio International Convention NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its CEO, Ivor Elrifi, will be giving an oral presentation during the Bio International Convention in Boston, MA. Mr Elrifi’s presentation will cover the recent clinical findings of Tiziana’s lead drug candidate, i...

 PRESS RELEASE

Tiziana Life Sciences Announces Interview Highlighting Intranasal Fora...

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch